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Summary
Objectives: To characterize the molecular events underlying cartilage injury in the early phase of mono-iodoacetate-induced osteoarthritis
(OA) in rats.
Methods: Experimental osteoarthritis was induced by intra-articular injection of 0.03 mg mono-iodoacetate (MIA) in Wistar rats. Animals were
killed 2, 5, 10, 15 and 20 days post-injection. Synovial tissue and standardized biopsies from different areas of knee cartilage were examined.
Proteoglycan synthesis (35S incorporation) and gelatinase activities (zymography), semi-quantitative RT-PCR and immunohistochemistry for
IL1, iNOS, COX2 and PPAR, were performed on these samples.
Results: Changes in proteoglycan synthesis and gelatinase activities were time and site-dependent. Proteoglycan synthesis inhibition was
maximal by day 2 while the highest gelatinase activities were observed at day 5. Central part of patella and posterior plateaus and condyles,
i.e. the weight-bearing cartilage areas, were the most affected.
IL1 and iNOS transcripts were induced early in cartilage at time of maximal proteoglycan synthesis inhibition, especially in weight-bearing
areas. COX-2 was slightly up-regulated whereas PPAR gene expression remained unchanged. Gene expression profile in synovium
paralleled that of cartilage, except for PPAR which was up-regulated at day 15 and 20.
Immunostaining for IL1 and iNOS showed that proteins were located in diseased cartilage areas at early stage of the experimental OA (day
2). At later time-points (day 20), IL1 and iNOS were expressed in perilesional areas whereas immunostaining became below control level
for COX-2 and PPAR.
Conclusions: Time-dependent degradation of cartilage after injection of low dose of MIA (0.03mg) into rat knee joint can be related to early
loss of proteoglycan anabolism, increased gelatinase activities and expression of IL1 and downstream inflammatory genes. Increased
susceptibility to MIA in weight-bearing areas of cartilage further indicate that MIA-induced experimental OA is a relevant model to study not
only metabolical but also biomechanical aspects of human OA.
© 2003 OsteoArthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Introduction
Osteoarthritis (OA) is a degenerative joint disease which
affects a large population and results in significant mor-
bidity and disability. The clinical condition is characterized
by focal cartilage destruction, concomitant hypertrophic
reactions in the bone, including osteophyte formation at the
joint margins, and inflammation of the synovium1.
In an attempt to study the pathophysiology of the early
phases of the disease and to identify new targets for
therapeutic modalities, numerous experimental models
that mimic aspects of human OA have been developed.
Unlike spontaneous OA which has slow onset and probably
originates in unknown genetic predisposition, experimental
induction of OA in animals makes it possible to influence
the onset and the course of the disease. OA can be
induced by different ways, including load impact induced
trauma, surgically- or enzymatically-induced joint instability,
extracellular matrix damage induced by collagenase or
disturbance of chondrocyte metabolism induced by mono-
iodoacetate (MIA), vitamin A or steroids2. In mice, injection
of MIA led to a strong inhibition of proteoglycan synthesis
in the central part of the patella and the medial part of
the tibial plateau3,4. Subsequently, the loss of locomotor
activity, and the severity of cartilage lesions in patella were
directly related to the injected dose of iodoacetate, allowing
for a grading of OA severity in rats5.
The involvement of several cytokines and enzymes has
been reported in human OA. IL1 has been shown to be
one of the most deleterious cytokine for cartilage in vivo
and in vitro: it can inhibit proteoglycan anabolism and
promote degradation of extracellular matrix components
through activation of metalloproteinases (MMPs)6–8. The
chondroprotective efficacy of IL1 receptor antagonist in
animal models of OA further supports the deleterious
effects of IL1 on cartilage9,10. IL1 can mediate its effects
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at least through induction of COX-2 and iNOS expression,
which produce the inflammatory mediators prostaglandins
and nitric oxide (NO), respectively11–15. Indeed, NO
interferes with chondrocyte functions, resulting in loss of
cartilage matrix through MMPs activation, induction of
apoptosis or inhibition of proteoglycan and type II collagen
synthesis16–18. The role of PGE2 in proteoglycan degra-
dation is more controversial: while Di Battista showed
that PGE2 increased proteoglycan synthesis in vitro19,
IL1-induced production of PGE2 contributed to cartilage
degradation in human osteoarthritic joint tissues20.
Besides, the identification of endogenous factors which are
able to modulate IL1-dependent cartilage degradation is
still under investigation. In vitro, activation of peroxisome
proliferators activated receptor gamma (PPAR) has
been shown to counteract IL1-induced expression of
inflammatory genes or MMPs in chondrocytes and
synoviocytes21–23.
Experimental models of OA often play a pivotal role
in new target discovery/validation and drug evaluation.
Nevertheless, while MIA-induced effects on cartilage
and especially on chondrocytes metabolism have been
reported in details, the events involved in initiation and
progression of this experimental OA are still poorly under-
stood. Therefore, we designed the present study to
describe the molecular processes underlying cartilage
injury during the course of the MIA-induced OA, thereby
providing evidence for the contribution of IL1 and its
effectors (iNOS, COX2) and PPAR in the early phase of
this model. Since focal erosions have been documented in
human, it remains to examine to what extent different sites
within the same joints are affected in a course of a
chemically induced OA. Thus, we attempted to relate
variations in gene expression to regional differences in
MMPs activity and proteoglycan synthesis.
Materials and methods
ANIMALS
Male Wistar rats (150–175 g), obtained from Charles
River (L’arbresle, France) were housed under controlled
temperature and lighting conditions with food and water
ad libitum. Animals were acclimatized to the laboratory
environment for one week before experiment. Our local
Animal Care and Use Committee approved the experimen-
tal protocols, and guidelines for laboratory procedures were
followed at all times.
EXPERIMENTAL DESIGN
Rats were injected in both knee joints with MIA (0.03 mg/
knee) (Sigma St Quentin Fallavier, France) in a volume of
50 µl sterile saline. Rats injected with saline alone served
as controls. At day 2, 5, 10, 15, and 20 post-injection,
synovia, patellae, femoral condyles and tibial plateaus
were collected. Synovia were immediately frozen at −80°C
for RNA extraction and measurement of MMPs activity.
Patellae, femoral condyles and tibial plateaus were pro-
cessed for ex vivo incorporation of Na35SO4 into cartilage,
RNA extraction, immunohistochemical analysis or measure
of MMP activity.
HISTOLOGICAL STUDY
Knee joints from saline and MIA-injected rats were
fixed for 24 h in 4% paraformaldehyde immediately after
sacrifice, decalcified in rapid bone decalcifier (RDO, Apex
engineering, Plainfield, U.S.A.) for 4 h, further fixed in 4%
paraformaldehyde and embedded in paraffin. Sections
(5 µm thick) of femoro-tibial joints were rehydrated in a
graded series of ethanol and stained for collagen and
proteoglycan with Safranin-O-Fast-Green.
PROTEOGLYCAN SYNTHESIS
Cartilage explants – i. e. patellae, femoral condyles and
tibial plateaus-were placed for 3 h at 37°C in a humidified
5% CO2 atmosphere with 0.6 µCi/ml Na235SO4 (Amersham,
Les Ulis, France) in RPMI Hepes 1640 medium sup-
plemented with 2 mM L-glutamine, 100 µg/ml streptomycin,
and 100 IU/ml penicillin. After 5 washings in saline,
explants were fixed overnight at room temperature in 0.5%
cetylpyridinium chloride dissolved in 10% formalin buffer.
Explants were then decalcified for 6 h in 5% formic acid,
and biopsies (2 mm diameter) were punched out from the
surrounding tissues. Biopsies were dissolved in 0.5 ml
Soluene (Packard, Rungis, France) overnight at 42°C. The
35S content of each individual biopsy was measured by
liquid scintillation counting (Packard, Rungis, France).
GELATIN ZYMOGRAPHY
Dissected intact cartilage was immediately homogenized
in 0.5 ml homogenization buffer (50 mM Tris HCl, pH 7.4,
300 mM KCl, and 2.5 mM MgCl2) using Polytron PT(Kinematica, Luzern, Switzerland). Aliquots (10 µl) of
cartilage homogenates containing 0.25–2 µg total protein
were mixed with nonreducing sodium dodecyl sulfate-
polyacrylamide gel electrophoresis sample buffer and elec-
trophoresed in 10% polyacrylamide gels containing
1 mg/ml type A gelatin from porcine skin, at 20 mA constant
current for 1.5–2 h at 4°C. Following electrophoresis, gels
Table I
Gene (length) Primers (forward-reverse) Cycles Tm
L27 5′-TCC-TGG-CTG-GAC-GCT-ACT-C-3′ 25 61°C
225 bp 5′-CCA-CAG-AGT-ACC-TTG-TGG-GC-3′
IL1 5′-TGA-AAG-CTC-TCC-ACC-TCA-ATG-G-3′ 35 55°C
367 bp 5′-TCC-ATG-GTG-AAG-TCA-ACT-ATG-TCC-3′
COX-2 5′-TCC-AGA-TCA-CAT-TTG-ATT-GAC-AG -3′ 30 59°C
443 bp 5′-TGT-GGG-AGG-ATA-CAT-CTC-TCC-3′
iNOS 5′-AGC-AGA-ATG-TGA-CCA-TCA-TGG-ACC-3′ 30 60°C
433 bp 5′-ATG-CAG-ACA-ACC-TTG-GTG-TTG-AAG-3′
PPAR 5′-ATA-AAG-TCC-CTT-CCC-GCT-GAC-CAA-AGC-3′ 30 64°C
523 bp 5′-CGG-TCT-CCA-CTG-AGA-ATA-ATG-ACA-GC-3′
Osteoarthritis and Cartilage Vol. 12, No. 4 285
were washed twice for 20 min with 2.5% Triton X-100 in Tris
buffered saline (50 mM Tris HCl, pH 7.5, 150 mM NaCl) to
allow protein to renature. Gels were then incubated 20–
40 h at 37°C in substrate buffer (50 mM Tris HCl, pH 8,
10 mM CaCl2, and 0.02% NaN3), stained with Coomassie
R250 for 30 min and destained for 1 h. Gelatin-degrading
enzymes were visualized as clear bands, indicating pro-
teolysis of the substrate protein. Gels were scanned and
Control





Fig. 1. Effects of MIA on cartilage matrix. Safranin-O-fast-green staining on representative sections of tibial plateaus from rats killed at day
2, 5, 10 and 20 after 0.03 mg MIA injection. Original magnification ×40.
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analyzed by a Viber Lourmat (Torey, France) imaging
system. Molecular weight markers (Bio-Rad) and positive
controls, human MMP-2 and MMP-9 (Oncogen Research
Products, Boston, MA) were used in all gels.
REVERSE TRANSCRIPTION-POLYMERASE CHAIN REACTION
(RT-PCR)
Explants were decalcified for 18–24 h with EDTA
165 mM pH=7.4 in RNA later (Ambion, Huntingdon, U.K.)
before separation of the cartilage layer from the underlying
bone. Total RNAs from synovium and cartilage were iso-
lated using a commercially available phenol-chloroform
solution (Trizol) (Sigma, St Quentin Fallavier, France).
Integrity of RNA pool was verified by electrophoresis.
mRNAs (2 µg) were reverse transcribed for 1.5 h at 37°C
using M-MLV reverse transcriptase (200 U) (Gibco BRL,
Cergy Pontoise, France) and anchored 15 mer oligo-dT
primers (100 pmol) (MWG biotech SA, Courtaboeuf,
France). PCR amplification was then performed with 1/10th
of RT products with Taq polymerase (2.5 U) (Gibco BRL,
Cergy Pontoise, France) using specific primers (MWG
biotech SA, Courtaboeuf, France). The conditions for
amplification were: denaturation at 94°C for 45 s, hybridiz-
ation of primers at defined temperature for 45 s and
elongation at 72°C for 45 s (see Table I).
Fig. 2. A and B.
Fig. 2. Time-course of proteoglycan synthesis in cartilage biopsies following MIA administration. Proteoglycan synthesis was measured by
35SO42− incorporation in standardized biopsies of cartilage (localization indicated in the corresponding scheme) after intra-articular injection
of 0.03 mg MIA (patella (A), plateaus (B), femoral groove (C) and condyles (D)). Results are expressed as the percentage of 35S
incorporation in cartilage from MIA-injected rats vs control animals (N=6). (*=P<0.05; **=P<0.01; ***=P<0.001).
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As an internal control, the same RNA preparation was
also subjected to RT-PCR analysis for the housekeeping
gene L27, encoding a ribosomal protein. The PCR products
were analyzed by 0.2 µg/ml ethidium bromide staining
in 1.5% agarose gel. Quantification was performed with
Geldoc 2000 software (Biorad, Marnes-la-Coquette,
France).
IMMUNOHISTOCHEMICAL ANALYSIS
Femoral condyles and tibial plateaus were fixed in 4%
paraformaldehyde for at least 24 h, decalcified for 4 h in
RDO, further fixed for 24 h in paraformaldehyde, and then
embedded in paraffin. Paraffin sections (5 µm thick) were
deparaffinized in toluene, and hydrated in a graded series
of ethanol. Slices were incubated subsequently in BSA 4%
as blocking reagent for at least 2 h, then overnight at 4°C
with a polyclonal primary antibody (COX-2, 10 µg/ml, sc-
7951 Santa-Cruz; iNOS, 2 µg/ml, sc-650 Santa-Cruz; IL1,
6 µg/ml, sc-7884 Santa-Cruz; PPAR, 6.7 µg/ml, sc-7196
Santa-Cruz) (Tebu, Le Perray-en-Yvelines, France) and
finally with biotinylated secondary antibody (1 µg/ml) for
45 min at room temperature. Signal was then amplified with
preformed avidin-biotinylated horseradish peroxidase com-
plexes for 45 min at room temperature and, staining was
developed with 3,3′-diaminobenzidine (0.05% in hydrogen
peroxide) (Novostain super ABC kit, Novocastra, Kington,
U.K.).
STATISTICAL ANALYSIS
For RT-PCR analysis, each value is a mean of at least
four animals (both knees from one animal being pooled in
one sample). The RT-PCR analysis were repeated twice for
one set of animals. Six samples for the determination of
proteoglycan synthesis were analyzed from three indepen-
dent experiments. The results was analyzed by ANOVA,
and P values less than 0.05 were considered significant
(*=P<0.05; **=P<0.01; ***=P<0.001).
Fig. 2. C and D
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Results
MIA INDUCES HISTOLOGICAL MODIFICATIONS IN RAT ARTICULAR
CARTILAGE
A single injection of a low dose of MIA (0.03 mg) induced
cartilage lesions in the posterior (severe in central part and
moderate at the margin) but not in the anterior part of the
tibial plateaus (Fig. 1). In comparison to saline–injected
controls, early changes included matrix depletion in super-
ficial layer by day 2 and a rarefaction of chondrocytes in
primarily affected areas. By day 5, proteoglycan loss
spread out to the deep zone of the tibial plateaus and
appeared in the superficial layers of the femoral condyle.
From day 10 to day 20 of the time-course, hypertrophic
chondrocytes disappeared, the width of the lesion
increased, as well as the number of necrotic chondrocytes,
except in the lateral part of the articular surface. By day 20,
proteoglycan depletion was enhanced with fibrillation of the
cartilage surface and some subchondral bone sclerosis in
few animals.
MIA-INDUCED VARIATIONS OF PROTEOGLYCAN SYNTHESIS ARE
TIME- AND SITE-DEPENDENT
Proteoglycan synthesis, assessed by ex vivo incorpor-
ation of radiolabeled sulfate into cartilage, was examined
in cartilage biopsies from different areas of the knee joint
(Fig. 2), allowing to distinguish central/peripheral parts of
Fig. 3. Gelatinase activities assessed by zymography in knee joint cartilage and synovium homogenates prepared from tibial plateaus,
femoral condyles and synovium obtained 5 or 20 days after injection of 0.03 mg MIA.
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the patella, anterior/posterior and lateral/medial parts of
tibial plateaus and femoral condyles. MIA injection induced
time- and site-dependent changes in articular cartilage:
strong biphasic variations of proteoglycan synthesis were
observed in central patella, femoral groove, posterior
plateaus and condyles while they were less intense in
peripheral patella, anterior plateaus and anterior condyles.
In patella, a strong inhibition of 35S incorporation was
observed at day 2, especially in the central part, and was
followed by a transient recovery at day 5 and day 10.
However, proteoglycan synthesis decreased again at day
15 and returned to basal level at day 20. No significant
reduction in cartilage anabolism was also noted in the
peripheral part (day 2 and day 5), but proteoglycan syn-
thesis rate remained stable over control level at later time
points (Fig. 2A).
In tibial plateaus (Fig. 2B), proteoglycan synthesis was
strongly inhibited in posterior parts (P2 and P4) from day 2
(more than 80%) to day 15, with recovery at day 20. In the
anterior areas (P1 and P3), proteoglycan synthesis was
less inhibited (20 to 40%) at day 2, returned to control level
at day 5 and tended to overcome basal level at later time
points.
In femoral groove, 35S incorporation was inhibited by
about 50% at day 2 only. An overshoot ranging from 38% to
65% was observed at day 10 (Fig. 2C). As for tibial
plateaus, proteoglycan synthesis varied depending on the
site of femoral condyles (Fig. 2D) with inhibition restricted
to the posterior areas (biopsies 4 and 6), although recovery
remained incomplete at day 20.
MIA-INDUCED GELATINASE ACTIVITIES ARE TIME- AND
SITE-DEPENDENT
Gelatin zymography of each cartilage area (patella, tibial
plateaus, femoral groove, femoral condyles) exhibited time
and site-dependent variation in the activity of MMP-2 (latent
form 72 kD, active form 66 kD) and MMP-9 (latent form
97 kD) at day 2, 5, 10, 15 and 20 following MIA injection. In
synovium, MMP-9 activity was not detected, and only minor
changes in MMP-2 were observed between samples from
MIA-injected rats and controls (Fig. 3).
In tibial plateaus, an increase in MMP-2 (latent form) was
detected in posterior areas (biopsies 2 and 4) and, to a
lesser extend in anterior ones (biopsies 1 and 3) at day 5
and day 20 (Fig. 3). However, an increase was observed for
the active form in the posterior areas.
In femoral groove and posterior condyles, an increase in
MMP-2 activity was measured whatever the time-point,
whereas there were no significant differences in anterior
condyles. MMP-9 activity did not vary between cartilage
from MIA-injected rats and controls, except at day 20 in
anterior condyles (Fig. 3).
In patella, no variation of gelatinase activity was
observed in the course of the model (data not shown).
IL1, COX2, iNOS, PPAR mRNAs ARE EXPRESSED IN THE EARLY
PHASE OF MIA-INDUCED OA
As shown in Fig. 4, IL1 expression increased signifi-
cantly at day 2 in patella and synovium (6-fold and 2.7-fold,
respectively). A 2-fold increase was observed at day 2 for
COX-2 mRNA in both tissues, and for PPAR mRNA in
patella only (Fig. 4A). At day 5, genes expression returned
to control levels except for PPAR in synovium, for which
expression increased strongly at day 5 and 10 (Fig. 4B).
No significant variation in mRNAs expression was
detected in the overall plateaus or condyles (data not
shown). However, by separating the different cartilage
areas, we were able to detect at day 2 a strong increase in
IL1 expression (2 to 4.8-fold) in posterior plateaus (Fig.
5A), and an induction of IL1 and iNOS in femoral groove
(Fig. 5B). Expression levels in anterior areas of plateaus
and in condyles did not differ from control levels (Fig. 5A
and 5B). The level of PPAR expression was too weak to
detect any significant variation in these biopsies.
IL1, COX2, iNOS, PPAR PROTEINS ARE EXPRESSED DURING
MIA-INDUCED OA
Immunohistochemical analysis of serial sections showed
that IL1, COX2, iNOS and PPAR were expressed in
condyles and plateaus from control rats (Fig. 6). Two days
after MIA injection, expression of iNOS, COX2 and IL1
was enhanced in most chondrocytes from the superficial
layer of cartilage. At day 5, 10, 15 and 20, IL1, iNOS
and COX2 expressing chondrocytes were located at the
periphery of the lesions whereas staining decreased pro-
gressively until disappearance in diseased areas. Basal
expression of PPAR was down-regulated in MIA-treated
rats from day 2 to day 20 despite a transient and moderate
immunoreactivity at day 15.
Discussion
In this study, we determined the time-course of cartilage
changes within various parts of the knee joint in the
MIA-induced experimental OA in rat. We observed that loss
of proteoglycan anabolism occurred early in the disease in
specific cartilage areas but lessened at later time points:
proteoglycan synthesis was back to control levels at day
20 whatever the biopsy tested. Besides, chondrocytes
exhibited enhanced gelatinase activities from day 2 in our
model and a peak of gelatinase activities was measured at
day 5. This suggests that the early phase of MIA-induced
OA is not only characterized by a decrease in the bio-
synthetic activity of cartilage but also by an increase in
catabolic activities. At later time-points, positive immuno-
staining for MMP-2, MMP-9 and MMP-3 (stromelysin 1)
was observed at the margins of the lesions (data not
shown), and gelatinase activities remain detectable during
the whole course of the disease, demonstrating a long-
standing catabolic process in cartilage. These results are in
agreement with previous study from Janusz24 who showed
that collagenase and gelatinase activities increased in the
knee cartilage of rats injected with 0.25 mg MIA. Therefore,
a low dose of MIA with respect to previous dose-response
study5 seems to be sufficient to induce matrix degrading
enzymes and to investigate the molecular events leading to
OA lesions.
Describing the molecular events underlying changes
in cartilage metabolism, we showed that chondrocytes
in posterior areas, which were the most sensitive to
the disturbing effect of MIA on chondrocytes functions,
expressed pro-inflammatory genes (IL1, iNOS, COX2)
very early in the disease. Noteworthy, their kinetic of
expression varied concomitantly to changes in cartilage
anabolism, since maximal expression was observed at time
corresponding to maximal loss of proteoglycan synthesis.
In addition, immunohistochemical analysis indicated that
IL1, COX-2 and iNOS were expressed in superficial layers
of cartilage. These layers are known to be very responsive
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to the deleterious effect of IL1 on cartilage25. Taken
together, these results demonstrate that the expression of
typical factors involved in human OA such as IL1, COX2,
iNOS and MMPs paralleled the initiation and progression of
cartilage lesions during the MIA-induced experimental OA.
Previous in vitro study demonstrated that exposure to
IL1 decreased mRNA expression of PPAR in articular
cells21. In the MIA model, we observed a lack of PPAR
protein expression and we failed to show any down regu-
lation of PPAR transcription in the articular cartilage,
whatever the area tested. This could be due to a very low
level of basal expression of the gene in rat cartilage which
does not preclude that induction of PPAR activity by
synthetic ligands could have beneficial effects in articular
arthropathy. By contrast, a two- to three-fold increase in
PPAR expression was observed in the synovium at day 5
and day 10 following MIA injection. Since natural ligands of
PPAR are supposed to be peculiar prostaglandins26,
previous induction of COX-2 might provide endogenous
ligands to the newly synthesized receptors and might
contribute to a limitation of synovial inflammation27. This
suggests that inhibition of COX-2 activity would improve
pain and acute inflammation, but could affect some
endogenous control of joint homeostasis. This might
explain, at least in part, the failure of NSAIDs to limit
cartilage destruction in the MIA model (unpublished data).
In order to take into account the focal nature of OA
lesions, we performed histological staining in anterior
or posterior areas of the femoro-patellar joint, and exam-
ined proteoglycan anabolism and gelatinase activities in
biopsies from several locations within the same joint. The
evaluation of these three parameters showed that cartilage
Fig. 4. Kinetics for inducible nitric oxide synthase (iNOS), cyclooxygenase 2 (COX2), interleukin-1 beta (IL1), peroxysome proliferator
activated receptor gamma (PPAR) messenger RNA (mRNA) expression in synovium and cartilage from the whole patella of rats injected
with 0.03 mg MIA. After extraction from tissues collected at various time-points, total RNA was subjected to RT-PCR analysis using specific
primers for each gene. PCR amplification of L27 was performed on the same RNA preparation as an internal control for the relative amounts
of template. Experiments were performed in duplicate with at least four animals for each time-point. Results are expressed in arbitrary units
relative to control samples±SEM (*=P<0.05; **=P<0.01).
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lesions occurred in the posterior parts of plateaus and,
except for gelatinase activities, in the posterior parts of the
condyles and in the central part of the patella. Because
of the flexed position of rats hindpaws, central patella
together with posterior plateaus and condyles corre-
spond to weight-bearing areas of the knee joint. Therefore,
susceptibility to MIA would depend on biomechanical
forces heterogeneously applied to cartilage and result in
focal lesions4. There is significant evidence that chondro-
cytes respond to changes in their shape and volume by
regulating their metabolic activity and gene expression.
These results emphasize the importance of using cartilage
Fig. 5. Relative levels of IL1, iNOS, COX-2 and PPAR mRNA expression in biopsies collected from plateaus (A) and condyles (B), 2 days
following 0.03 mg MIA injection. PCR amplification of L27 was performed on the same RNA preparation as an internal control for the relative
amounts of template. Experiments were performed in duplicate with four animals. Results are expressed in arbitrary units relative to control
samples±SEM (*=P<0.05).
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from identical joint areas when examining both proteogly-
can metabolism and gene expression in chondrocytes. The
relationship between mechanical stress and the incidence
of OA is not clear in vivo, although Fermor et al. 28 showed
recently that mechanical compression increased signifi-
cantly NO and PGE2 production through a NO-dependent
pathway. Therefore, we propose that MIA might first impair
the function of the most metabolically active chondrocytes
which are located mainly in weight-bearing areas, through
inhibition of glycolysis. As a consequence, chondrocytes
Fig. 6. IL1, iNOS, COX-2 and PPAR proteins 2 or 20 days after intra-articular injection of 0.03 mg MIA. Immunohistochemistry was
performed on representative sections of femoro-tibial joints from MIA-injected and control rats. Original magnification ×100.
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may respond by increasing the production of iNOS, IL1,
COX2. Additionally, our data suggest that the expression of
IL1 in these weight-bearing areas may result in MMPs
activation and matrix degradation. Thus, injection of low
dose of MIA points out loading contribution to OA patho-
physiology and mimics the mechanical component of
human OA. Although the driving role of abnormal mechan-
ical forces has been well described in experimental OA
induced by instability of the joint29, their pathophysiological
contribution to a metabolically-induced disease is de-
scribed here in details. Therefore, characterization of MIA-
induced OA provides information on both chondrocytes
metabolism and possibly joint biomechanics.
Since MIA injection induces IL1 expression, site-
dependent changes in cartilage may also result from het-
erogeneous distribution of cytokine receptors in articular
cartilage. Recently, Westacott et al. showed that loading
induces TNFRI but not TNFRII expression at the mem-
brane of alginate encapsulated chondrocytes isolated from
OA patients30. In human samples, the potential for TNF-
induced loss of cartilage is also enhanced near the articular
surface of weight bearing zones, where many receptors are
located31,32. Although no relationship between IL1RI or
IL1RII expression and site sensitivity was observed for
IL1, Shlopov et al. 33 showed that chondrocytes located
around OA lesions have a greater IL1-binding capacity than
those located at more distal sites, and significant regional
variation in sensitivity to IL1 was observed within the
same OA femoral condyles34. Since early expression of
IL1, COX2 and iNOS were found in the same location
as cartilage lesions in weight bearing areas, our results
suggest that a combination of mechanical and MIA-
mediated metabolic stress induces degrading mediators,
which, in turn, initiate focal lesions. Once OA has begun,
one may hypothesize that loading and pressure applied on
altered cartilage could also modify locally the expression
or distribution of pro-inflammatory cytokine receptors
and therefore enhance chondrocyte response to these
cytokines (TNF, IL1 . . .) and their effectors (iNOS,
COX2 . . .).
Human OA is often not diagnosed until the disease has
reached an advanced stage, when the joints become
functionally impaired and painful. Therefore, animal models
provide a unique way of understanding the early events of
the pathology and evaluating new therapeutic targets. In
this study, we have shown that OA-like arthropathy induced
by a low dose of MIA mimics the focal character of human
OA. We also showed that focal lesions seem to originate
in site-specific induction of pro-inflammatory factors and
metalloproteinases. Since local IL1 induction appears to be
the first molecular event following MIA injection, the next
step of the study should be the use of an in vivo anti-IL1
strategy.
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